

**Venue:** Exhibition, Ground Level  
**Presentation:** Monday 21 July, 12:30-14:30

The Poster Exhibition is open from Mon 21 - Thu 24  
 July from 10:00 to 18:30.

Late breaker posters will be displayed for the duration  
 of the conference.

Authors of late breaker posters in **Track A, C and E** will  
 stand by their posters on Monday, 21 July between 12:30  
 and 14:30 to answer questions and provide further  
 information on their study results.

## Track A > Basic and Translational Research

<b>PE01</b>	<b>Innate immune responses and function during HIV infection</b>
LBPE01	<b>HDAC inhibitors modulate innate immune responses to HIV by altering IFI16 localization and IFN signalling in macrophages</b> <i>K. Jønnsen, A. Laustsen, J.H. Egedal, K. Thavachelvam, S.R. Paludan, M. Tolstrup, M. Jakobsen</i> Denmark
<b>PE02</b>	<b>Virus-specific cellular immunity</b>
LBPE02	<b>In youths with perinatally acquired HIV-1 infection, Gag-specific CD8 T cell proliferation is associated with higher levels of TGF-beta1 and the preservation of gut-homing T cells: the ANRS-EP38-IMMIP Study</b> <i>J. Le Chenadec, D. Scott-Algara, S. Blanche, C. Didier, T. Montange, J.-P. Viard, C. Dollfus, V. Avettand-Fenoel, C. Rouzioux, J. Warszawski, F. Buseyne</i> France
<b>PE03-04</b>	<b>Host cellular factors and latency</b>
LBPE03	<b>Host anti-HIV-1 microRNAs 28, 125b, 150, 223, and 382 previously implicated in viral latency in CD4+ memory T cells do not act directly on HIV-1 gene expression</b> <i>G. Bernardi, J. Bayliss, P. Revill, D. Purcell</i> Australia
LBPE04	<b>DC interactions lead to an inducible HIV reservoir in proliferating CD4+ T cells</b> <i>N. Kumar, R.M. van de Sluis, V.A. Evans, S.R. Lewin, P.U. Cameron</i> Australia
<b>PE05</b>	<b>Tissue reservoirs</b>
LBPE05	<b>Preferential infection of central memory T cells that express CCR6 and CXCR3 in HIV-infected patients on ART may contribute to a larger HIV reservoir in rectal tissue</b> <i>J. Anderson, R. Fromentin, N. Chomont, E. Sinclair, G. Khoury, A. Solomon, M. Smith, P. Cameron, L. Epling, R. Hoh, F. Hecht, S. Deeks, S. Lewin</i> Australia
<b>PE06-07</b>	<b>Targeting and eradication of reservoirs</b>
LBPE06	<b>Immunological correlates of HIV-1 DNA decline during latency reversal with panobinostat in patients on suppressive cART</b> <i>M. Tolstrup, S. Vigano, R. Olesen, C. Brinkmann, M. Buzon, L. Østergaard, T. Rasmussen, M. Lichterfeld, O. Søgaard</i> Denmark

LBPE07

**Multidose vorinostat in HIV-infected individuals on effective ART leads to an increase in regulatory T cells but no change in inducible virus or HIV-specific T cells**

*F. Wightman, J.H. Elliot, A.E. Solomon, R. Fromentin, F.A. Procopio, J. Zeidan, T. Spelman, N. Chomont, P.U. Cameron, R.P. Sekaly, S.R. Lewin*  
Australia

PE08

**Host restriction factors (including APOBEC and TRIM)**

LBPE08

**Computational modeling of Vif antagonists using the Vif crystal structure reveals small molecule binding pockets and the Vif dimerization domain**

*H. Smith, R. Bennett, J. Salter, G. Morales*  
United States

PE09

**Novel vectors and strategies**

LBPE09

**HIV-1 MicroCube vaccine: crystalline micro-particles as antigen carriers for vaccination**

*R. Ffrench, A. Brass, L. Hilton, N. Mangan, S. Brandler, C.-S. Lay, M. Hijnen, J. Mak, H. Mori, J. Taylor, A. Mansell, F. Coulibaly*  
Australia

PE10

**Interactions of HIV with other pathogens (including HPV)**

LBPE10

**HIV-induced epithelial-mesenchymal transition in orogenital mucosal epithelia facilitates HPV infection and HPV-associated transformation**

*S. Tuqizov, R. Herrera, E. Isaacson Wechsler, P. Veluppillai, D. Greenspan, J. Palefsky*  
United States

## Track C > Epidemiology and Prevention Research

PE22

**Molecular epidemiology**

LBPE22

**The global spread of HIV-1 CRF01\_AE epidemic: a phylogeographic analysis**

*I. Mamais, J. Albert, K. Angelis, G. Magiorkinis, A. Hatzakis, O. Hamouda, D. Struck, J. Vercauteren, A.M.J. Wensing, I. Alexiev, B. Åsjö, C. Balotta, R.J. Camacho, S. Coughlan, A. Griskevicius, Z. Grossman, A. Horban, L.G. Kostrikis, S.J. Lepej, K. Liitsola, M. Linka, C. Nielsen, D. Otelea, R. Paredes, M. Poljak, E. Puchhammer-Stöckl, J.C. Schmit, A. Sönnnerborg, D. Staneková, M. Stanojevic, C.A.B. Boucher, A.-M. Vandamme, D. Paraskevis*  
Romania

PE23

**Monitoring and evaluation (other)**

LBPE23

**Average time to enrollment in HIV care among adults who tested HIV+ between 1990 and 2012 and enrolled on care between October 2004 - September 2012**

*D. Mzaga, J. Nondi, V. Sambu, B. Kilama, R. Josiah, A. Ramadhani, D. Mmbando*  
Tanzania, United Republic of

PE24

**Prevention for trans-genders**

LBPE24

**Inclusion of transgender persons in pre-exposure prophylaxis (PrEP) research: a review**

*D.J. Escudero, T. Kerr, D. Operario, M.E. Socias, O. Sued, B.D. Marshall*  
United States

PE25

**Prevention of TB among people living with HIV**

LBPE25	<p><b>Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of toxicity when combined with antiretroviral therapy</b></p> <p><i>C. Kimcheng, T. Sopheap, C. Bopha, L. Natalie, J. van Griensven, L. Lynen</i> Cambodia</p>	PE44	<p><b>Interventions to improve coverage and impact of PMTCT services</b></p>
PE26-27	<p><b>Male circumcision</b></p>	LBPE44	<p><b>Option B in Rwanda: determinants of uptake of a complete PMTCT package of interventions across PMTCT prongs 2, 3 and 4 in the national PMTCT program (2010-2012)</b></p> <p><i>L. Tsague, P. Mugwaneza, A. Lyambabaje, A. Umubyeyi, J. Humuza, F. Mwanyumba, N. Shema, V. Mutabazi, S. Nsanzimana, R. Muhayimpundu, A. Irakoze, O. Mukabayire, E. Mutaganzwa, C. Lombard, D. Mbori-Ngacha, D. Jackson</i> UNICEF</p>
LBPE26	<p><b>Time to complete wound healing post-circumcision using the PrePex device in Maputo, Mozambique</b></p> <p><i>M. Mahomed, B. Cummings, E. Necochea, D. Bossemeyer, L. Nhambi, T. Ferreira, H. Muquingue</i> Mozambique</p>	PE45	<p><b>Sexual and reproductive health and HIV services: delivery models and costs</b></p>
LBPE27	<p><b>Oestrogen can increase keratin thickness of the inner foreskin epithelium potentially forming a physical barrier to HIV entry</b></p> <p><i>A. Pask, C. Bell, R. Short</i> Australia</p>	LBPE45	<p><b>Integrating syphilis, gonorrhoeae (GC) and chlamydia (CT) screening into an HIV/cervical cancer screening outreach program: a model for increasing access to same-day test and treatment for curable STIs</b></p> <p><i>P.M. Chilwesa, P.D. Njobvu, E. Mulenga, Y. Mulenga, S. Banda, C.N. Mukwasa, M.L. Sinkala</i> Zambia</p>
PE28	<p><b>PrEP</b></p>	PE46	<p><b>Prevention and treatment programmes for adolescent and young key populations</b></p>
LBPE28	<p><b>Tenofovir and emtricitabine pharmacokinetics in plasma and saliva following a single dose of TDF 600mg/FTC 400mg: implications for on demand PrEP (ANRS Ipergay)</b></p> <p><i>J. Fonsart, B. Loze, S. Morel, C. Capitant, J. Chas, I. Charreau, E. Netzer, G. Peytavin, G. Pialoux, C. Delaugerre, J.-M. Molina, The ANRS Ipergay study group</i> France</p>	LBPE46	<p><b>Respondent-driven sampling survey of risk behaviors of young key affected populations in Thailand: findings and implications for future programming</b></p> <p><i>C. Lee, M. Steinhaus, L. Johnston, R. Gass, T. Siraprasasiri, P. Sirinirund</i> Thailand</p>
PE29	<p><b>Impact of treatment on prevention</b></p>	PE47	<p><b>Community-led programmes and organizations, including for key populations</b></p>
LBPE29	<p><b>Higher antiretroviral treatment coverage is associated with lower adult HIV infection rates: analysis of 51 low and middle-income countries</b></p> <p><i>A. Hill, A. Pozniak, K. Heath, A. Raymond, N. Ford</i> United Kingdom</p>	LBPE47	<p><b>Co-creation government - community partnership: using Facebook page as ARV stock-out monitoring tool</b></p> <p><i>A. Wardhana</i> Indonesia</p>
PE30	<p><b>Approaches to improving adherence to prevention interventions</b></p>	PE48	<p><b>Role of community organizations in linking people to HIV services and strengthening the health system</b></p>
LBPE30	<p><b>Spatial analysis of police encounters and addiction treatment center locations in Tijuana, Mexico</b></p> <p><i>D. Werb, A. Vera, J. Arredondo, L. Beletsky, P. Gonzalez-Zuniga, S. Strathdee, T. Gaines</i> United States</p>	LBPE48	<p><b>Moulding change - for a better tomorrow - by ourselves, for ourselves</b></p> <p><i>S. Ghosh</i> India</p>
PE31	<p><b>Efficacy of structural interventions and social protection</b></p>	PE49	<p><b>Use of implementation research to support the evidence-based response to HIV</b></p>
LBPE31	<p><b>Estimating the number of HIV and hepatitis C cases averted through the implementation of federal prison-based needle exchange programs in Canada</b></p> <p><i>D. Werb</i> Canada</p>	LBPE49	<p><b>Community-based testing approaches for gay and bisexual men: a participatory peer ethnography</b></p> <p><i>J. Ellard, R. Lake, M. Dean, S. Donohoe</i> Australia</p>
Track E >	<p><b>Implementation Research, Economics, Systems and Synergies with other Health and Development Sectors</b></p>	PE50-51	<p><b>Innovative approaches to sharing/disseminating programme data at national, regional, district, site and community levels</b></p>
PE43	<p><b>Voluntary counselling and testing programmes</b></p>	LBPE50	<p><b>Reducing HIV-related stigma and discrimination in health care settings: an initiative from Thailand</b></p> <p><i>N. Pudpong, P. Prakongsai, K. Srithanaviboonchai, S. Chariyalertsak, C. Chariyalertsak, P. Smutrapapoot, P. Sirinirund, T. Siraprasasiri, S. Ongwandee, P. Benjarattanaporn, B. Otto, L. Nyblade</i> Thailand</p>
LBPE43	<p><b>Comparing the information and support needs of different population groups in France in preparation for 2014 government approval for HIV self-testing</b></p> <p><i>T. Greacen, K. Champenois, D. Kersaudy-Rahib, J.-M. Le Gall, N. Lydié, J. Ghosn</i> France</p>	LBPE51	<p><b>Cohort analysis of ART facilities in Sudan</b></p> <p><i>W. Hassan, M. Abdella, N. Mahmoud</i> Sudan</p>

**Venue:** Exhibition, Ground Level

**Presentation:** Tuesday 22 July, 12:30-14:30

The Poster Exhibition is open from Mon 21 - Thu 24 July from 10:00 to 18:30.

Late breaker posters will be displayed for the duration of the conference.

Authors of late breaker posters in **Track B and D** will stand by their posters on Tuesday, 22 July between 12:30 and 14:30 to answer questions and provide further information on their study results.

## Track B > Clinical Research

**PE11** **Viral load measurement (including point of care diagnostics)**

LBPE11 **Performance of dried blood spots prepared under clinical conditions to identify virologic failure among adults and children on antiretroviral therapy in Kenya**

*M.E. Schmitz, S. Agolory, M. Umuro, M. Jungbae, J. Ombayo, L.N. Broyles, I. Mukui, K. Alwenya, J. Orwa, K. Ouma, J. Wagude, S. Mwalili, L. Ng'ang'a, C. Yang, C. Zeh*  
Kenya

**PE12-15** **Hepatitis C**

LBPE12 **Minimum target prices for production of direct-acting antivirals and associated diagnostics for developing countries**

*A. Hill, N. Van de Ven, B. Simmons, S. Khoo, N. Ford, J. Fortunak*  
United Kingdom

LBPE13 **The HCV care 'cliff': high burden of HCV disease and poor access to HCV services among people who inject drugs in India**

*S.S. Solomon, S.H. Mehta, A.K. Srikrishnan, M. Sulkowski, G.M. Lucas, C.K. Vasudevan, A. McFall, D.D. Celentano, S. Anand, S.H. Iqbal, O. Laeyendecker, S. Saravanan, M.S. Kumar, S. Solomon, T.C. Quinn*  
United States

LBPE14 **Hepatitis C virus RNA and genotype, IL28B genotype, and liver fibrosis scores in a regional cohort of HIV-infected HCV-exposed patients under routine HIV care in Asia**

*N. Durier, K. Ruxrungtham, A. Avihingsanon, N.V. Kinh, B.V. Huy, E. Yunihastuti, A. Sanityoso, S.F.S. Omar, I.A. Yee, P. Morgan, D. Boettiger, G. Matthews*  
Thailand

LBPE15 **Ledipasvir/sofosbuvir is safe and effective as a single-tablet-regimen for treatment of patients with genotype 1 chronic hepatitis C virus, including those with compensated cirrhosis**

*M.S. Sulkowski, K. Kowdley, P. Ruane, T. Hawkins, R. Elion, K. Workowski, A. Mills, M. Subramanian, X. Ding, S. Seyedkazemi, R.H. Hyland, J.C. Yang, P.S. Pang, J.G. Mchutchison, N. Afdhal, D. Wyles*  
United States

**PE16** **Early stage clinical trials: phase I/II**

LBPE16 **The MiniZID study: a randomized controlled trial on safety of reduced dose (400 mg) of zidovudine compared with standard dose (600 mg) in HIV-infected patients starting antiretroviral therapy**

*M. Rougemont, P. Nchotu Ngang, J.-C. Fampou, G. Menga, B. Stoll, C. Delhumeau-Cartier, A. Hill, A. Calmy*  
Switzerland

**PE17** **Clinical trials: post-licensing**

LBPE17

**Non-inferiority of dual-therapy (DT) with lopinavir/ritonavir (LPV/r) plus lamivudine (3TC) vs. triple-therapy (TT) with LPV/r plus two nucleos(t)ides (NRTIs) for maintenance of HIV viral suppression: 48-week results of OLE study**

*J.M. Gatell, J.R. Arribas, P.M. Girard, R. Landman, J. Pich, J. Mallolas, M. Martinez, J.F. Zamora, V. Estrada, M. Crespo, D. Podzamczar, J. Portilla, F. Dronda, J.A. Iribarren, P. Domingo, F. Pulido, M. Montero, H. Knobel, A. Cabié, L. Weiss, OLE Study Group*  
Spain

**PE18-19** **Simplification (with one- or two-agent regimens) and switch studies**

LBPE18 **Switching to dual therapy (atazanavir/ritonavir+lamivudine) vs. standard triple therapy (atazanavir/ritonavir+2 nucleos[t]ides) is safe and effective in virologically suppressed patients: 48-week results of a randomized clinical trial (SALT study)**

*J.A. Perez-Molina, R. Rubio, A. Rivero, J. Pasquau, I. Suárez, M. Riera, M. Estébanez, J. Santos, J. Sanz, J. Troya, A. Mariño, A. Antela, J. Navarro, H. Esteban, GESIDA 7011 Study Group*  
Spain

LBPE19 **HARNESST study: ritonavir-boosted atazanavir (ATV/r)+raltegravir (RAL) switch study in virologically suppressed, HIV-1-infected patients**

*J. van Lunzen, A. Pozniak, J. Gatell, A. Antinori, I. Klačuk, O. Serrano, A. Baakil, M. Yu, P.-M. Girard*  
Germany

**PE20** **Pharmacology / pharmacokinetics / pharmacogenomics / role of therapeutic drug monitoring**

LBPE20 **Pharmacokinetics of VM-1500 20 mg and 40 mg in healthy and HIV-infected patients**

*R. Murphy, W. Ratanasuwan, P. Werarak, A. Koryakova, B. Berzins, V. Bichko*  
United States

**PE21** **Eradication / reservoir depletion: impact of ART and non-ART treatment**

LBPE21 **Allogeneic bone marrow transplantation in two HIV-1 infected patients shows no detectable HIV-1 RNA or DNA, and a profound reduction in HIV-1 antibodies**

*K.K. Koelsch, W.J. Hey-Cunningham, S.C. Sasson, C. Pearson, Y. Xu, M. Bailey, K.H. Marks, B.M. Hiener, S. Palmer, J. Zaunders, J.J. Post, S.T. Milliken, A.D. Kelleher, D.A. Cooper*  
Australia

**Track D > Social and Political Research, Law, Policy and Human Rights**

**PE32** **Adaptation to living with HIV for individuals, families and communities**

LBPE32 **Factors that affect quality of life among HIV patients not on antiretroviral therapy attending an urban clinic in Uganda**

*D.M. Mwesigire, A. Katamba, F. Martin, J. Seeley*  
Uganda

**PE33** **People with disabilities**

LBPE33	<p><b>Effective HIV programme and policy interventions for people with disabilities in Sub-Saharan Africa: a literature review</b></p> <p><i>K.L. McCormack, R.T. Mathur, E. Friel, S. Murphy</i> Ireland</p>	LBPE42	<p><b>Strengthening advocacy and policy-setting capacity of networks of Women living with HIV: lessons from a five-country programme evaluation</b></p> <p><i>N. Damji, J.D. Buchanan, T. Atsbeha</i> United States</p>
PE34	<p><b>Other vulnerable social groups, including in specific contexts</b></p>		
LBPE34	<p><b>How are “children affected by HIV” really affected? Significant differences in among orphaned and non-orphaned children under the age of five</b></p> <p><i>A. Clark</i> United States</p>		
PE35	<p><b>Legal protection of people living with HIV and key populations</b></p>		
LBPE35	<p><b>Using strategic litigation to ensure access to HIV treatment for prisoners in southern Africa in countries which do not guarantee the right to health</b></p> <p><i>P. Patel</i> South Africa</p>		
PE36	<p><b>Human rights of people living with HIV and key populations</b></p>		
LBPE36	<p><b>Rescue operation to save OST patient from Crimea</b></p> <p><i>P. Skala, T. Tretskaya, O. Burgay, A. Basenko, V. Kolomiets, T. Tamara</i> Ukraine</p>		
PE37	<p><b>HIV counselling and testing in health care and community settings</b></p>		
LBPE37	<p><b>The European HIV testing week pilot, 2013</b></p> <p><i>B.C. West, J. Begovac, B. Collins, A.-I. Von Lingen, N. Dedes, V. Delpech, R. Fernandez, N. Giordano, L. Power, D. Raben, A. Zakowicz, J. Lundgren</i> Netherlands</p>		
PE38	<p><b>Couples- or family-centred approaches</b></p>		
LBPE38	<p><b>The acceptability of and barriers to male partner participation in PMTCT programs: a cross sectional survey among male partners of pregnant or lactating women in Zimbabwe</b></p> <p><i>V. Chitiyo, K. Webb, T. Ndoro, S. Mtongwiza-Page, P. Mbetu, D. Patel, B.U.E. Engelsmann</i> Zimbabwe</p>		
PE39-40	<p><b>Incentives, micro-finance and other economic support</b></p>		
LBPE39	<p><b>Modeling cash incentives vs. oral preexposure prophylaxis in high-risk African women: the Cash-PreP Study</b></p> <p><i>E. Richardson, J. Loftus, S. Collins, K. Tram, T. Kung, V. Boggiano, A. Zolopa, L.-G. Bekker, J. Jones</i> United States</p>		
LBPE40	<p><b>Incentive-based approach for enrollment and participation in HIV and STIs prevention program for female sex workers</b></p> <p><i>F. Majeed, M. Aftab</i> Pakistan</p>		
PE41	<p><b>Policy analysis and indicators of policy effectiveness</b></p>		
LBPE41	<p><b>Donor government funding for HIV in low- and middle-income countries: can we achieve an AIDS free generation?</b></p> <p><i>J. Kates, A. Wexler, E. Lief</i> United States</p>		
PE42	<p><b>Policy development processes, influences and constraints</b></p>		